Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
Approximately 20% of vascular patients treated with acetyl salicylic acid (i.e., aspirin) demonstrate less than expected platelet inhibition – putting them at a four-fold increased risk of adverse cardiovascular events. Low-dose rivaroxaban (2.5 mg twice daily) in combination with low-dose aspirin h...
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Frontiers Media S.A.
2022-08-01
|
| Schriftenreihe: | Frontiers in Cardiovascular Medicine |
| Schlagworte: | |
| Online Zugang: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.912114/full |